Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Current assets
Cash and cash equivalents	$ 46,832	$ 35,627
Marketable securities, short-term	79,777	135,930
Prepaid expenses and other current assets	5,544	6,749
Total current assets	132,153	178,306
Marketable securities, long-term	9,443	59,968
Restricted cash	232	232
Other assets, long-term	393	486
Total assets	142,221	238,992
Current liabilities
Accounts payable	682	5,648
Accrued clinical trial expenses	9,884	15,344
Accrued expenses and other current liabilities	7,792	6,615
Debt, short-term	3,598	0
Total current liabilities	21,956	27,607
Debt, long-term	27,053	29,419
Other liabilities, long-term	39	150
Total liabilities	49,048	57,176
Commitments and contingencies (Note 10)
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of September 30, 2025 and December 31, 2024	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 60,573,425 and 60,094,083 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively	6	6
Additional paid-in capital	514,382	506,985
Accumulated deficit	(421,324)	(325,127)
Accumulated other comprehensive income (loss)	109	(48)
Total stockholders’ equity	93,173	181,816
Total liabilities and stockholders’ equity	$ 142,221	$ 238,992